NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $0.70 0.00 (-0.14%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$0.70 0.00 (-0.29%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Context Therapeutics Stock (NASDAQ:CNTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Context Therapeutics alerts:Sign Up Key Stats Today's Range$0.69▼$0.7250-Day Range$0.55▼$0.9152-Week Range$0.49▼$2.75Volume44,321 shsAverage Volume207,536 shsMarket Capitalization$62.70 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company Overview Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Read More Context Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreCNTX MarketRank™: Context Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 505th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContext Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.77% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Context Therapeutics has recently decreased by 4.76%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.77% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Context Therapeutics has recently decreased by 4.76%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Context Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CNTX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $107,206.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.80% of the stock of Context Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Stock News HeadlinesContext Therapeutics Reports Second Quarter 2025 Operating and Financial ResultsAugust 6 at 4:11 PM | globenewswire.comContext Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025July 25, 2025 | msn.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 7 at 2:00 AM | Banyan Hill Publishing (Ad)Context Therapeutics Approves Reverse Stock Split AmendmentJune 12, 2025 | tipranks.comCo-Founder of Context Therapeutics Martin Lehr Buys 10% More SharesJune 11, 2025 | finance.yahoo.comContext Therapeutics: Undervalued Cancer FighterJune 10, 2025 | seekingalpha.comContext Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO MeetingJune 2, 2025 | globenewswire.comContext Therapeutics Inc.: Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerMay 29, 2025 | finanznachrichten.deSee More Headlines CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.05 on January 1st, 2025. Since then, CNTX shares have decreased by 33.4% and is now trading at $0.6990. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) released its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.03. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an IPO on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Context Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS). Company Calendar Last Earnings8/06/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTX CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Context Therapeutics$5.50 High Price Target$9.00 Low Price Target$4.00 Potential Upside/Downside+686.8%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-29.78% Return on Assets-29.08% Debt Debt-to-Equity RatioN/A Current Ratio48.81 Quick Ratio48.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book0.55Miscellaneous Outstanding Shares89,700,000Free Float87,192,000Market Cap$62.70 million OptionableNot Optionable Beta1.89 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:CNTX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.